Harnessing the brain’s immune system to fight neurodegeneration
CereSpir is targeting the emerging field of immuno-neurology via a novel mechanism for the treatment of Parkinson’s disease and other neurodegenerative diseases
Read MoreCereSpir has the most advanced therapeutic agent targeting LRRK2 neurotoxicity and the only AICD inhibitor in development
Read More
- CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier
- CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR’S Parkinson’s Disease Development Program for Itanapraced
- CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease